Connect with us

Featured

Cosmos Holdings Inc (NASDAQ: COSM) Mammoth Short Squeeze Rising Fast as CEO Grigorios Siokas Buying More (COSM Rapid Growth Through Acquisition)

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is an enormous short squeeze that is rocketing up the charts while the overall market are weak. On Monday COSM was up over 10% at one point but closed at $0.57 up 6.5% while the Nasdaq lost just under 500 points on the day. COSM is quickly going viral and is currently among the top most trending stocks on Stocktwits, the top most mentioned stock on the sub reddit Short Squeeze, and there are dozens of Youtube channels reporting on it and private discord groups buying COSM from all over the world. 

While COSM was shorted into oblivion the Company is strong recently reporting $12 million in revenues in Q3 as well as rapid growth through acquisition with 3 major acquisitions currently on the table. COSM is led by able CEO Grigorios Siokas, a high level pharmaceutical executive Mr. Siokas is a major shareholder in Ippokratis Pharmaceuticals, Thrakis Pharmaceuticals, Thessalias Pharmaceuticals, and ZED Pharma SA. Since 2019, Mr. Siokas has invested over $10.6M at an average price of $5.25 of his personal wealth into Cosmos. More recently Mr. Siokas acquired another 1,131,098 shares on Friday adding to the 481,079 shares acquired Thursday adding to his previous buy of 800,000 shares at $0.62 earlier last week. This comes after Mr. Siokas acquired 12.5 million shares price at $0.12 as part of a securities purchase agreement in October.  

COSM Tuesday Update: COSM is coming back moving back over $0.50 in late day trading Tuesday. The stock saw a significant drop this morning after the Company filed an 8k on Monday that stated the board had approved several matters including: “(6) to authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at their discretion.” This does not mean COSM is going to do a reverse split. It means the BOD has approved it so they can affect a RS at their discretion if they need to. It’s certainly in managements best interest not to do a reverse stock split. However, the Nasdaq listing is more important so they will use it if they have to. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings IncCosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts | Micro Cap Daily (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The group in engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in EU and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Management is focused on Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, and Local & Direct to Pharmacy Wholesale. Check out the Company’s latest presentation here.

In Q3, 2022 Cosmos reported $12 million in revenues and made a number of important advancements including raising $7.5 million via a public offering, entered into an agreement to restructure its warrents to avoid dilution, announced an agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus and much more. 

COSM Rapid Growth Though Acquisition:

Cosmos has a plan for rapid growth through acquisition; currently the Company is evaluating acquisition targets that allows it to expand its distribution reach and/or vertically integrate into its supply chain of the products. COSM is also actively pursuing accretive acquisitions that offer long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure. 

COSM acquisitions currently on the table:  

  • Entered into an LOI to acquire ZipDoctor Inc., a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. 
  • Entered into an agreement to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 
  • Entered into a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies. 

https://twitter.com/MoonMarket_/status/1599850735323136000

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Cosmos Holdings Inc. (Nasdaq: COSM) | LinkedIn

Recent News: Cosmos Health Provides a Summary Regarding Recent Share Activity and Reiterates its Belief and Commitment to the Financial Strength and the Growth and Profitability of the Company 

On December 2 COSM provided a summary regarding recent share activity, including the participation of CEO, Greg Siokas on all capital raises. Management reiterates its belief in the financial strength of Cosmos Health, and its commitment to the growth and profitability of the Company. 

In February and October of 2022 Cosmos successfully conducted two separate rounds of financings, with the combined proceeds of $13.5M. Furthermore, the Company has noted significant exercises of warrants in the month of November. As such, management now expects that by the end of Year End 2022, debt should decline by roughly 50% versus prior year levels. 

Mr. Siokas has not sold any shares and has no plans to sell any of his shares. 

Greg Siokas, Chief Executive Officer of Cosmos Health stated, “I am excited to see Cosmos emerge in to in a stronger financial position. We have had two successful capital raises in 2022, both of which I happily participated in for a combined amount of $3M. Since 2019, I have invested over $10.6M at an average price of $5.25 of my personal assets in Cosmos, as I have always believed in its growth and profitability prospects. My interests have always been and will continue to be aligned with those of shareholders, and I am constantly working to make sure shareholder value is realized. Given our new financial stability, I am hopeful about the future of Cosmos and our ability to rapidly grow as an international health and wellness company with multiple strong brands. I want to thank our shareholders and our team members who have helped us through this journey.” 

 For More on COSM Subscribe Right Now!

Currently trading at a $46 million market valuation COSM os is 83,797,481 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 10 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1. As for the Nasdaq delisting COSM appealed it and has (until otherwise annouinced) until January 23 to get the bid over $1 We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Featured

Femasys’ (NASDAQ: FEMY) FemaSeed Receives FDA Nod: A Game-Changer for Infertility Treatment

Published

on

Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.

FemaSeed:

It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.

Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.

Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.

But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.

In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.

We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by DigitalMarketingAgency from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.